US2003147905A1PendingUtilityA1
Therapeutic compounds
Priority: Mar 16, 2000Filed: Jan 8, 2003Published: Aug 7, 2003
Est. expiryMar 16, 2020(expired)· nominal 20-yr term from priority
Inventors:Charles Nicolette
A61P 35/00A61P 37/04A61K 38/00C07K 14/71A61P 15/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides synthetic compounds, antibodies that recognize and bind to these compounds, polynucleotides that encode the compounds, and immune effector cells raised in response to the presentation of these compounds. The invention further provides methods for inducing an immune response and administering immunotherapy to a subject by delivering the compounds of the invention.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound having the structure:
2 . A compound having the structure:
3 . A compound having the structure:
4 . A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 774, 775, 776, 777, 778, 779, and 780 are F, L, F, D, P, T, and T respectively.
5 . A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 774, 775, 776, 777, 778, 779, and 780 are F, L, Y, Y, G, T, and T respectively.
6 . A peptide comprising the amino acid sequence of SEQ ID NO: 2 wherein amino acids 774, 775, 776, 777, 778, 779, and 780 are F, L, F, T, P, T, and I, respectively.
7 . A polynucleotide that encodes an amino acid sequence comprising the amino acid of SEQ ID NO: 3.
8 . A polynucleotide that encodes an amino acid comprising the amino acid sequence of SEQ ID NO: 5.
9 . A polynucleotide that encodes an amino acid comprising the amino acid sequence of SEQ ID NO: 7.
10 . A polynucleotide that encodes a peptide of any of claims 4 to 6 .
11 . An antibody that specifically recognizes and binds a compound of any of claims 1 to 3 .
12 . A method for inducing an immune response in a subject, comprising delivering an effective amount of a compound of any of claims 1 to 3 to the subject.
13 . The method of claim 12 , wherein the compound is delivered in the context of an MHC molecule.
14 . The method of claim 13 , wherein the MHC molecule presents the compound on the surface of an antigen presenting cell.
15 . The method of claim 12 , wherein the compound is delivered as a polynucleotide that encodes the compound.
16 . A method of immunotherapy, comprising administering to a subject an effective amount of an antibody of claim 11 .
17 . An immune effector cell that has been raised in vitro or in vivo in the presence and at the expense of an antigen presenting cell that presents the compound of any of claims 1 to 3 in the context of an MHC molecule.
18 . A method of adoptive immunotherapy, comprising administering an effective amount of the immune effector cell of claim 17.Join the waitlist — get patent alerts
Track US2003147905A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.